anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention concerns extrudates having high surface area materials and at least one metal ion adsorbed onto the high surface area material. The extrudates may be breathable films, multilayer laminates and pultruded articles. The extrudates may be made into storage and packaging material to reduce odor and retard the ripening of fruit. The extrudates, if in the form of a breathable film or multilayer laminate may be used as outer cover material for personal care products like diapers, adult incontinence products, training pants and the like. The high surface area particle-containing extrudate may be made by adding modified nanoparticles to a filler before the filler is treated with a fatty acid. Alternatively, a filler previously treated with a fatty acid may be modified by subjecting the filler to sonic energy in the presence of an aqueous solution of metal ions and nanoparticles.
This study aims to monitor the structural and functional changes of chronically compressed spinal cords longitudinally after surgical decompression in vivo. Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI). To quantitatively investigate the structural deficits, T1/T2 MRIs will delineate the gross morphology of the spinal cord, CSF, and surrounding anatomical structures, while DTI will quantify the fiber orientation and integrity within the spinal cord. BOLD-based functional MRIs will assess the local hemodynamic changes and neuron activities in response to the motor or sensory stimulation along the C3 to C8 spinal nerve levels. The MRI evaluations will be applied to the same cervical myelopathy (CM) patient before surgery and 3 and 6 months post-surgery, when clinical recovery reaches a plateau9. Clinical examination will include neurological evaluation, Japanese Orthopaedic Association (JOA) scoring assessment, and clinical electrophysiological evaluation.
PURPOSE:To obtain a hair growth agent, capable of promoting hair growth regardless of symptoms or physical constitution and effective against various alopecias. CONSTITUTION:A hair growth agent is obtained by blending a phthalazinone derivative or 2,3-dihydroimidazo[2,1-a]phthalazinone derivative expressed by formula I or II (R<1> is straight-chain or branched chain hydrocarbon group; R<3> is H or alkyl), e.g. 4-butyl-1(2H)phthalazinone expressed by formula III as an essential ingredient in an amount of normally 0.001-20wt.%, preferably 0.10-10wt.% (0.01-10wt.% when the dosage form of the hair growth agent is a liquid such as a suspension or a paste such as an ointment) in the total composition of the hair growth agent with other ingredients. The resultant hair growth agent has excellent hair growth effects and is capable of promoting the hair growth in applied sites in its application to the scalp, etc. Furthermore, the hair growth gent is used as a medicine for external use and the dosage form is not especially limited. The dosage form is preferably a liniment such as an ointment, a lotion, a tonic, a spray, a suspension or an emulsion.
Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
Participants will receive a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 1, followed by a single oral dose of moxifloxacin tablet (Treatment B) in treatment period 2, followed by a single oral low dose of enpatoran tablet (Treatment C) in treatment period 3, followed by a single oral high dose of enpatoran tablet (Treatment D) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.
PURPOSE: A lipopeptide which is specifically conjugated to Fc region of an antibody and antigen recognizing lipid nanoparticle containing the same are provided to enhance transport efficiency of various drugs to target cells. CONSTITUTION: An antigen recognizing lipid nanoparticle contains an antibody to a lipid nanoparticle by non-covalent bond. The lipid nanoparticle contains Fc region binding lipopeptide in which Fc-binding peptide and lipid is conjugated by covalent bond. The Fc region binding peptide of the antivody is a branched peptide having an amino acid of structural formula 1 or peptide of amino acid of sequence number 1-5. The lipid is a compound of chemical formula 1. The lipid nanoparticle is liposome, micelle, emulsion, or solid lipid nanopaticle. A medicinal composition contains the antigen recognizing lipid nanoparticle, therapeutic agent or diagnostic agent.
Craniospinal irradiation (CSI) involving radiation (RT) of brain and spine, along with tumor-bed boost with or without chemotherapy, is the current standard treatment for medulloblastoma and other primitive embryonal tumors of the central nervous system (CNS). The delayed side effects following CSI include memory loss, hearing and balance difficulties, hormonal imbalance, and secondary cancers. Decline in memory severely affects the quality of life in long term survivors of these diseases. Hence, various strategies are being tried to prevent it. Memantine has been proven to effectively prevent the memory decline induced by RT. It is FDA-approved for Alzheimer's disease and is widely used in the children for several developmental disorders. With this study, we are trying to investigate the role of memantine in patients receiving CSI to prevent memory decline.

After screening for the study, eligible patients will be randomly allocated (by computerised system) to one of the two arms that are described as follows. Patients in the experimental arm (memantine) will be started on memantine, starting dose of the same will be 5mg once daily at bedtime for 1 week, followed by 5mg twice daily for 1 week, and finally increased to the full dose of 10 mg twice daily for 6 months. Patients will continue on radiation and chemotherapy (when indicated) as per schedule. All patients in the study will undergo neurocognitive evaluation, the time points for which will be pre-radiation (baseline), 6 months post-RT, 1-year post-RT, and annually after that for 5 years from radiation. Following completion of RT or treatment, standard follow-up protocols will include a clinical examination 3 monthly for the first 2 years, followed by 6 monthly visits till 5 years post-RT. No additional risk is expected from the current study other than the common side effects of the standard treatment. Based on the results from the study, if primary endpoints are achieved, it will establish the role of memantine in preventing memory decline from CSI, which can be used as a standard treatment measure to help patients in the future.
BACKGROUND: Complementary and alternative medicine (CAM) is frequently used in the general population, yet only limited data are available regarding the prevalence of these medications in patients with chronic kidney disease (CKD). Hence, our study aimed to explore the prevalence and types of CAM in Taiwanese patients with CKD.
METHODS: A cross-sectional questionnaire survey was conducted by face-to-face interview of 275 pre-dialysis patients without dialysis treatment or kidney transplant at an outpatient nephrology clinic in Taiwan from March 2021 to June 2023. The study outcomes were the prevalence of CAM, CAM types, reasons for using CAM, and sources of information about CAM.
RESULTS: Overall, 128 patients (46.5%) were using CAM, but no significant differences from non-CAM users in the various CKD stages (p = 0.156) were found. CAM usage was high in the age range of 20-60 years and duration of CKD ≤ 5 years (p < 0.05). The most commonly used type of CAM was nutritional approaches (79.7%), followed by other complementary health approaches (26.6%). The most commonly utilized modalities of CAM were vitamins and minerals (38.3%), and only 27.1% of patients disclosed their CAM use to their physicians. The most common sources of information about CAM were family and friends, cited by 66% of the participants. Health promotion and a proactive attitude were reported by 40% of users as the reasons for using CAM.
CONCLUSIONS: The present study provides data on the CAM usage among CKD patients and adds to the increasing evidence on CAM use. Because some of these practices have safety concerns, better education from healthcare providers on the risks and benefits of CAM therapy is needed by CKD patients.
BACKGROUND: Activation of mast cells plays an important role in brain inflammation. CD300a, an inhibitory receptor located on mast cell surfaces, has been reported to reduce the production of pro-inflammatory cytokines and exert protective effects in inflammation-related diseases. Peroxisome proliferator-activated receptor β/δ (PPARβ/δ), a ligand-activated nuclear receptor, activation upregulates the transcription of CD300a. In this study, we aim to investigate the role of PPARβ/δ in the attenuation of germinal matrix hemorrhage (GMH)-induced mast cell activation via CD300a/SHP1 pathway.
METHODS: GMH model was induced by intraparenchymal injection of bacterial collagenase into the right hemispheric ganglionic eminence in P7 Sprague Dawley rats. GW0742, a PPARβ/δ agonist, was administered intranasally at 1 h post-ictus. CD300a small interfering RNA (siRNA) and PPARβ/δ siRNA were injected intracerebroventricularly 5 days and 2 days before GMH induction. Behavioral tests, Western blot, immunofluorescence, Toluidine Blue staining, and Nissl staining were applied to assess post-GMH evaluation.
RESULTS: Results demonstrated that endogenous protein levels of PPARβ/δ and CD300a were decreased, whereas chymase, tryptase, IL-17A and transforming growth factor β1 (TGF-β1) were elevated after GMH. GMH induced significant short- and long-term neurobehavioral deficits in rat pups. GW0742 decreased mast cell degranulation, improved neurological outcomes, and attenuated ventriculomegaly after GMH. Additionally, GW0742 increased expression of PPARβ/δ, CD300a and phosphorylation of SHP1, decreased phosphorylation of Syk, chymase, tryptase, IL-17A and TGF-β1 levels. PPARβ/δ siRNA and CD300a siRNA abolished the beneficial effects of GW0742.
CONCLUSIONS: GW0742 inhibited mast cell-induced inflammation and improved neurobehavior after GMH, which is mediated by PPARβ/δ/CD300a/SHP1 pathway. GW0742 may serve as a potential treatment to reduce brain injury for GMH patients.
Methods and systems for predicting possible interactions between two or more drugs are disclosed. A plurality of documents is analyzed (212, 214) to extract medical relevant information. The extracted information comprises at least one first entity associated with at least one second entity. In addition, supplementary information is received (220) from a structured data source (220-1, 220-2). A graph is then created to represent the information extracted from the plurality of documents and the supplementary information from the structured data source (220-1, 220-2) in a unified scheme. The created graph comprises a plurality of nodes and a plurality of edges connecting the plurality of nodes. After the creation of the graph, the graph is analyzed (234) using machine learning techniques to identify at least one new edge. The identification of the at least one new edge is based on paths already included in the initially created graph. Based on the at least one new edge, probable drug-to-drug interactions are determined (236) and output.
Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.
50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injection as a fluid and nutrient replenisher.   
Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an osmolarity of 2.5 mOsmol/mL (calc.) and a pH of 3.2-6.5. May contain Hydrochloric acid and/or Sodium hydroxide for pH adjustment.   
The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit.   
Dextrose, USP is chemically designated C 6H 12O 6 • H 2O (D-glucose monohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has the following formula: 

Water for Injection, USP is chemically designated H 2O. 

The delivery device is composed of a 50 mL glass syringe barrel with rubber stopper, and custom molded IMS injector with Luer Connector.
The conventional ECG tracing will be obtained in the 12 leads of the frontal plane (DI, DII, DIII, aVR, AVL, AVF) and the horizontal plane (V1 to V6) and a 30-second rhythm trace in the DI lead. The diagnostic results of conventional ECG tracings will be: normal or abnormal; sinus rhythm, AF, atrial flutter or other non-sinus rhythm; intraventricular conduction disorder: left bundle branch block (BRE), right bundle branch block (BRD), right posteroinferior lower block (BDPI or left anterior superior (BDAS), isolated or associated; normal electrical axis, shifted to the right or shifted to the right) left, inconclusive and does not allow analysis due to poor technical quality.
BACKGROUND AND AIMS: Cardiovascular disease (CVD) is associated with inflammation and abnormal lipid metabolism. However, a single inflammatory index or a single lipid index cannot accurately predict the prognosis of CVD independently because it is prone to be affected by various confounding factors.
METHODS: This population-based cohort study included 6,554 participants from the China Health and Retirement Longitudinal Study (CHARLS) to investigate correlations. In the present study, the occurrence of CVD events such as stroke and heart disease was evaluated by considering self-reported diagnoses at the beginning of the study and during wave 4, and a restricted cubic spline model was used to investigate potential nonlinear relationships in addition to multivariate logistic regression models. Stratified analyses were performed to examine how sociodemographic characteristics may influence the results.
RESULTS: Seven years of follow-up (2011-2018) revealed that 786 people (11.99%) developed CVD. According to the adjusted model, the high-sensitivity C-reactive protein (hs-CRP)-to-high-density lipoprotein cholesterol (HDL-C) ratio is a contributing factor to CVD risk (OR 1.31, 95% CI 1.05-1.64). In addition, a nonlinear relationship was observed between the hs-CRP/HDL-C ratio and the occurrence of new CVD, stroke, or cardiac issues (Poverall <0.05, Pnonlinear <0.05). Moreover, noteworthy associations between the hs-CRP/HDL-C ratio and age were detected in the stratified analysis (P = 0.048), indicating that younger participants had more negative effects of a high hs-CRP/HDL-C ratio.
CONCLUSIONS: According to the present cohort study, a high hs-CRP/HDL-C ratio is a significant risk factor for CVD, new stroke, and heart problems. Early intervention in patients with increased hs-CRP/HDL-C ratios may further reduce the incidence of CVD, in addition to focusing on independent lipid markers or independent inflammatory markers.
The invention relates to a discovery of a significant biological activity of the Artichokes for the eradication of hepatitis C virus (HCV). Within short time and without side effects, the water extract of the globe Artichoke plant showed complete eradication of HCV. The biological evaluation was done on Egyptian volunteer patients infected with HCV. The monitoring of analysis was done through PCR before and after phytotherapy. In addition, the extract cured ascites, jaundice and normalized the liver enzymes SGPT & SGOT and showed significant activity against acne, obesity, diabetes, and has digestive effect and vermifuge. The dosage forms are capsules, tablets and syrups. The used parts of the plant are leaves, roots, seeds and/or flowers.
Background: Chronic inflammatory stimulation is a major risk factor for mild cognitive impairment. Mushroom consumption and inflammatory factors may play an important role in the pathogenesis of mild cognitive impairment. Additionally, consuming mushrooms can reduce the levels of inflammatory cytokines and preserve cognitive function. Therefore, this study aimed to investigate the relationship between mushroom consumption and serum inflammatory cytokines and mild cognitive impairment (MCI). Methods: Binary logistic regression was used to determine the relationship between mushroom consumption and MCI in 550 participants. Subsequently, mediation analysis was used to analyze the relationship between mushroom consumption, inflammatory factors, and the Montreal Cognitive assessment (MoCA) score in 248 participants. Results: Mushroom consumption was associated with MCI (odds ratio = 0.623, 95% confidence interval = 0.542-0.715, P < 0.001). The association between mushroom intake and MCI was mediated by interleukin-6 (IL-6) and hypersensitive C-reactive protein (hs-CRP), and the MoCA score was 12.76% and 47.59%, respectively. Conclusion: A high intake of mushrooms was associated with a low risk of MCI. Serum inflammatory factors including IL-6 and hs-CRP play a partial mediating role between mushroom intake and the MoCA score, and the underlying mechanism needs to be further explored.
The present invention relates to a novel protein called Insulin-Responsive Sequence DNA Binding Protein-1 (IRSBP-1) and nucleotide sequences that encode it. IRSBP-1 is capable of binding to nucleic acid regions associated with genes that respond when cells are exposed to insulin or insulin-like factors.  IRSBP-1 regulates genes important in mediating the insulin response in humans and animals and in regulating pathological conditions such as diabetes, obesity, insulin-resistant syndrome and cell proliferative disorders. The present invention provides nucleic acids that may be used as probes specific for hybridizing and detecting nucleic acid molecules that encode at least in part a region of the IRSBP-1 protein. Within the scope of the present invention are recombinant cells, tissues and animals containing non-naturally occurring recombinant nucleic acid molecules encoding IRSBP-1, including expression vectors for the expression of IRSBP-1, antibodies to the IRSBP-1 proteins, assays utilizing the IRSBP-1 polypeptide, and methods relating to all of the foregoing. Also within the scope of the present invention is the development of therapeutic and diagnostic agents that mimic, facilitate or inhibit the action of IRSBP-1, and/or are based on relationships to the structure and action of IRSBP-1.
Disclosed is a receptor PD-1-targeting non-antibody binding polypeptide or a derivate thereof. The non-antibody binding polypeptide comprises a main chain and at least one branch chain linked to the main chain. The amino acid sequence of the branch chain is shown as SEQ ID NO. 3, and the amino acid sequence of the main chain is shown as SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 7. The present invention further provides a polynucleotide encoding the non-antibody binding polypeptide, a recombinant vector, and a host cell. The present invention further provides a preparation comprising the non-antibody binding polypeptide or derivative thereof, the preparation being a drug or a cell labeling reagent. The present invention further provides a use of the non-antibody binding polypeptide or derivative thereof for preparing a tumor detection agent, an immunomodulatory drug, and an anti-tumor drug. The non-antibody binding polypeptide provided in the present invention has low molecular weight and good permeability, can be artificially synthesized, has low cost, no animal origin, high safety, and good binding ability to specific molecules, and has a function similar to or even better than that of a monoclonal antibody.
Those randomly assigned to the intervention-first group will complete initial inclusion tests and baseline tests at Visit 1. They will perform the VR audiovisual stimulation during Period 1 (week 1-6) and then repeat baseline tests at Visit 2. They will receive no intervention during Period 2 (week 7-12) and then repeat baseline tests at Visit 3.
All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
PROBLEM TO BE SOLVED: To obtain a carcinogenesis suppressing agent causing little side actions by using a specific derivative of a carotenoid compound separated from natural resources such as saffron. SOLUTION: This agent contains a crocetin disugar ester of formula (R1 and R2 are each gentiobiose or glucose) as an active component. The compound of the formula can be produced e.g. by separating crocetin (8,8'-diapocarotene diacid which is a compound of the formula wherein R1 and R2 are H) from saffron, etc., and converting the crocetin into digentiobiose ester (crocin), monoglucose monogentiobiose ester or diglucose ester. This carcinogenesis suppressing agent exists in a hot-water extract of the stigma of saffron being widely used as crude drug and food and exhibits the suppressing effect at a low concentration. Crocetin digentiobiose ester is especially effective among the above crocetin disugar esters.
All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital.